At Creative Biolabs, we provide comprehensive vaccine-based anti-monkeypox drug discovery services. Our strength lies in combining traditional insights with cutting-edge technologies, helping customers design innovative solutions that address the urgent global health need for effective monkeypox countermeasures. With over a decade in the vaccine industry, we are dedicated to developing high-efficiency and safe vaccines.
Overview
Monkeypox virus (MPXV) is a DNA virus of the Orthopoxvirus genus within the Poxviridae family. As a zoonotic pathogen, it primarily transmits from animals to humans, and also person-to-person. Infection typically presents with fever, body aches, swollen lymph nodes, and a characteristic rash. While often self-limiting, severe cases may lead to complications or prove fatal.
Fig.1 The transmission and clinical characteristics of monkeypox.1
-
Vaccine Strategies for Monkeypox
Effective vaccine strategies are paramount for controlling monkeypox. Traditional smallpox vaccines offer a degree of cross-protection due to the genetic similarities between orthopoxviruses. However, modern vaccinology offers advanced platforms that can provide improved efficacy, safety, and scalability. These include nucleic acid-based vaccines (mRNA and DNA), viral vector-based vaccines, recombinant protein vaccines, and inactivated virus vaccines. These diverse approaches allow for precise antigen presentation, eliciting robust humoral and cellular immune responses crucial for durable protection and potentially broader coverage against various orthopoxvirus strains.
Fig.2 Development of monkeypox vaccines.1
Anti-Monkeypox Drug Discovery Services Based on Vaccine at Creative Biolabs
Creative Biolabs offers a diverse range of vaccine-based anti-monkeypox drug discovery solutions tailored to meet specific research and development needs:
Our mRNA vaccine technology enables rapid design and LNP optimization for MPXV antigen delivery. Ideal for quick response, this platform offers high immunogenicity with reduced reactogenicity. We engineer mRNA constructs for optimal antigen expression, leading to robust immune responses.
VLPs are non-infectious, self-assembling protein structures mimicking viruses, presenting antigens highly immunogenically without live virus risks. Creative Biolabs' advanced VLP systems create stable, effective candidates eliciting strong humoral and cellular immunity against Monkeypox, offering a safe, potent prophylactic approach.
Utilizing established manufacturing processes, we develop inactivated virus vaccines for monkeypox. This effective, traditional approach chemically or physically inactivates MPXV, preserving antigenic integrity. Our focus ensures complete inactivation while maintaining immunogenicity, yielding safe, broadly accessible candidates for comprehensive protective immunity.
DNA vaccines provide a stable, cost-effective platform delivering MPXV antigens directly to host cells for immune response elicitation. Creative Biolabs optimizes plasmid design, promoter selection, and delivery methods to maximize expression and immunogenicity. This versatile tool offers long-term protection, advantageous for scalability and manufacturing ease.
Customized Service Workflow
At Creative Biolabs, our customized vaccine development process is meticulously designed to ensure precision and efficiency:
1
Client Consultation & Antigen Selection
-
Clients initiate the process by providing their preliminary ideas or specific requirements, outlining desired vaccine types, target protection effects, and preferred delivery methods.
-
Our expert team engages in in-depth discussions with the client to collectively analyze and confirm the most suitable MPXV antigens, such as major surface proteins or highly conserved antigenic epitopes. Concurrently, we determine the optimal vaccine strategy, whether it be a subunit, nucleic acid, or viral vector approach.
2
Vaccine Design & Construction
-
Based on the mutually selected antigen and vaccine strategy, we proceed with the intricate design of the vaccine vector, gene cloning, and optimization of protein expression systems, or the precise design and modification of nucleic acid sequences.
-
Throughout this phase, we emphasize key considerations, including the selection of the most effective vaccine delivery system and the appropriate adjuvant to enhance immunogenicity and safety.
3
Production & Quality Control
-
We efficiently produce the required vaccine candidates, encompassing various formats such as DNA, mRNA, virus-like particles, or inactivated viruses, utilizing our state-of-the-art facilities.
-
Stringent quality control measures are then applied, meticulously assessing purity, concentration, activity, stability, sterility, and endotoxin levels to ensure the highest product quality.
4
In Vitro Immunogenicity Evaluation
-
This stage involves evaluating the potential of vaccine candidates to induce immune responses at the cellular level. This includes assessing their ability to stimulate antigen-presenting cells, activate T cells or B cells, and detect the secretion of various cytokines.
5
In Vivo Immunogenicity & Efficacy Evaluation
-
Vaccine candidates are administered to appropriate animal models, including mice, rabbits, and non-human primates, to assess their performance in a living system.
-
We evaluate the humoral immune response by detecting neutralizing antibody titers and IgG/IgM levels in serum samples.
-
Cellular immune responses are thoroughly assessed, including T cell proliferation, cytokine secretion (such as IFN-γ, IL-2), and cytotoxic T lymphocyte (CTL) activity.
-
The antiviral protection effect is rigorously evaluated through MPXV challenge experiments conducted in a BSL-3 biosafety laboratory to quantify protective efficacy by parameters such as viral load reduction, pathological damage mitigation, and improvement in clinical symptoms.
6
Data Analysis & Report Delivery
-
Upon completion of evaluations, we provide comprehensive experimental data, detailed analysis reports, and professional data interpretation, along with actionable suggestions for further optimization.
-
Estimated Period: The estimated period for our customized vaccine-based anti-monkeypox drug discovery services typically ranges from 6 to 12 months, depending on the complexity of the chosen vaccine platform, the scope of antigen optimization, and the depth of in vivo efficacy studies required.
Click the button to contact us for service details and a custom quote.
Why Choose Creative Biolabs?
Integrated Platform
We offer a seamless, end-to-end pipeline from initial concept to preclinical validation, streamlining your research efforts.
Cutting-Edge Technology
Leveraging AI-driven insights and high-throughput screening, we accelerate antigen discovery and vaccine design, ensuring optimal performance.
Safety-Focused Design
Our emphasis on immunostimulatory sequences and tailored adjuvant systems aims to enhance efficacy while minimizing reactogenicity and side effects.
Broad Protection Strategies
We specialize in developing polyvalent vaccine strategies to ensure robust and broad protection against diverse monkeypox clades and related orthopoxviruses.
FAQs
How do I select the most suitable vaccine type for my project, considering the advantages and disadvantages of different platforms?
Selecting the optimal vaccine platform hinges on your project goals, desired immune response, and timeline. mRNA vaccines offer rapid development and high immunogenicity; viral vectors provide robust cellular immunity. Protein subunits with adjuvants achieve excellent safety, while inactivated vaccines leverage established manufacturing for broad accessibility. Our experts guide you through consultation to identify the best fit.
What are the key considerations for ensuring the durability of immune protection induced by a vaccine, and how do you optimize this aspect?
Durable immune protection is crucial. We optimize this by selecting highly conserved antigens resistant to viral escape, incorporating immunostimulatory sequences for enhanced, long-lasting responses, and carefully choosing adjuvants that promote sustained immunological memory. Our in vivo studies track long-term antibody titers and memory T-cell responses, providing comprehensive data on protection duration.
How do you conduct preliminary evaluations for the safety and potential side effects of vaccine candidates during the discovery phase?
Safety is paramount. During preclinical discovery, we use in silico modeling to predict off-target effects and reactogenicity. In vitro assays assess cytotoxicity and inflammatory responses. Our in vivo animal studies meticulously monitor for adverse reactions, local reactogenicity, and systemic toxicity post-vaccination, providing crucial preliminary safety data for clinical advancement.
Can you assist with the manufacturing process development for a lead vaccine candidate once it has been identified and validated?
Absolutely. While our primary focus is discovery and preclinical validation, we actively collaborate on scalable, cost-effective manufacturing process development. Our team optimizes production protocols, ensures quality control, and establishes robust manufacturing strategies amenable to large-scale production, facilitating the lab-to-industrial transition.
How does your high-throughput screening capability benefit the vaccine discovery process for monkeypox?
High-throughput screening (HTS) significantly accelerates the evaluation of numerous antigen variants and vaccine formulations. Our HTS platforms enable rapid assessment of immunogenicity, binding affinities, and preliminary safety across large candidate libraries. This efficiency quickly identifies lead candidates with desired characteristics, drastically reducing typical screening time and resources.
Can your services be adapted for therapeutic vaccine development, or are they primarily focused on prophylactic solutions?
While primarily focused on prophylactic vaccine development, our integrated platform is highly adaptable for therapeutic vaccine discovery. We investigate candidates designed to enhance immune responses in infected individuals, potentially aiding viral clearance or mitigating disease severity. Our expertise in immune modulation and antigen presentation develops therapeutic strategies complementing existing antiviral treatments.
Creative Biolabs offers a full range of vaccine-based anti-monkeypox drug discovery solutions to explore novel effective vaccines against monkeypox that have lower toxicity and fewer side effects. We combine traditional and cutting-edge technologies, including high-throughput screening, artificial intelligence, in vitro and in vivo platforms, and monkeypox detection services, to assist our global clients to discover effective vaccines against the monkeypox virus. We provide DNA and mRNA vaccine-based anti-monkeypox solutions, monkeypox-like particle-based vaccine solutions, as well as inactivated virus vaccine-based anti-monkeypox agent discovery solutions. If you have the intention to customize the vaccine-based anti-monkeypox drug discovery solutions, please don't hesitate to contact us.
Reference
-
Huang, Yong et al. “Monkeypox: epidemiology, pathogenesis, treatment and prevention.” Signal transduction and targeted therapy vol. 7,1 373. 2 Nov. 2022, doi:10.1038/s41392-022-01215-4. Distributed under Open Access license CC BY 4.0 , without modification.
